TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00598806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravesical dose of placebo instilled into the bladder post-TURBT
Study: NCT05918614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule; Route of administration: oral
Study: NCT01808339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).
Study: NCT00348322
Drug: Systane Free Lubricant Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02238236
Drug: Alesion®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry Syrup
Study: NCT02730728
Drug: 20ml bolus of 0.5% ropivicaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic
Study: NCT02730728
Drug: 0.2% Ropivicaine at 8 milliliter/hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic
Study: NCT02730728
Drug: 5ml bolus of 0.5% ropivicaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic
Study: NCT01320475
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)
Study: NCT03148899
Drug: Placebo Intranasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo has been compounded to be an inactive, blinded comparative to the oxytocin nasal spray.
Study: NCT01228149
Drug: Trabeculectomy with preoperative Diamox/DexaEDO treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filtrating glaucoma surgery, preoperative treatment with Diamox (acetazolamide) 28 day prior surgery. DexaEDO (dexamethasone) 7 days prior surgery
Study: NCT01228149
Drug: Trabeculectomy with preoperative Cosopt S treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filtrating glaucoma surgery, preoperative treatment with Cosopt S (dorzolamide/timolol) 28 day prior surgery.
Study: NCT01116635
Drug: doxorubicin, superabsorbent polymer microspheres, embolotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: varying doses of doxorubicin loaded onto SAP during embolization procedure. Pharmacokinetic analysis of elution profile through serum concentrations over 1 month period embolization of surgically resectable HCC with superabsorbent polymer microspheres loaded with doxorubicin from a single treatment. Phase I will follow a modified Fibonacci sequence (with pharmacokinetic analysis of serum doxorubicin) to determine mean tolerated dose (MTD), severe adverse reaction (SAE) and dose limiting toxicities (DLT) when microspheres are loaded with 25mg, 50mg, or 75mg of doxorubicin. Phase II will continue enrollment with the two highest tolerated doses. At least one month after treatment, all patients will undergo imaging and surgical resection of reference tumor, with assessment of degree of necrosis, microsphere distribution, and correlation with concentration of doxorubicin loaded onto microsphere.
Study: NCT00158782
Drug: GW786034
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.
Study: NCT00218569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02010567
Drug: CRLX101
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRLX101 is an experimental nanoparticle formulation of the anticancer agent camptothecin manufactured by Cerulean Pharma Inc..
Study: NCT02010567
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is an oral fluoropyrimidine pro-drug, metabolically converted to 5-fluorouracil after administration. It is indicated as adjuvant treatment in patients with stage III colorectal cancer (Dukes' C colon cancer), and as first-line treatment of metastatic colorectal cancer.
Study: NCT03068624
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01105117
Drug: Flolan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: per Prescribing Information
Study: NCT03441516
Drug: Alfoatirin® Tab. + Aripezil® Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline Alphoscerate 400 mg Oral Tablet bid + Donepezil 10 mg Oral Tablet qd for 24 weeks
Study: NCT03441516
Drug: Aripezil® Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg Oral Tablet qd for 24 weeks
Study: NCT01824420
Drug: Detrusitol 4mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group
Study: NCT00797017
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infection, starting with 12mcg/h (flexible dose)
Study: NCT00797017
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
Study: NCT00797017
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bone Fracture, starting with 12mcg/h (flexible dose)
Study: NCT00797017
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
Study: NCT00797017
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Other Deformity, starting with 12mcg/h (flexible dose)
Study: NCT00797017
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
Study: NCT00797017
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
Study: NCT02729870
Drug: Oral Glucose Gel
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive the following: are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
Study: NCT00374192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00253890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-3 at bedtime
Study: NCT01714960
Drug: MRZ-99030 eye drops 5mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01714960
Drug: MRZ-99030 eye drops 20mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01714960
Drug: Placebo to MRZ-99030 eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03094481
Drug: Bupivacaine hydrogen chloride , epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine
Study: NCT02531737
Drug: vargatef®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle
Study: NCT00265200
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3.0-4.0 mg by IV (in the vein), once a month for 6 months
Study: NCT02455440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03808844
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of 0.4 mg/kg followed by 0.2 mg/kg if needed.
Study: NCT00621244
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00508924
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02962102
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (medium chain triglyceride oil) orally daily x 5
Study: NCT03709914
Drug: ZTI-01 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZTI-01 intravenous (IV)
Study: NCT03709914
Drug: ZTI-01 75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZTI-01 intravenous (IV)
Study: NCT02504606
Drug: Besylsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipin besylate 6.944mg+Losartan K 100mg
Study: NCT02504606
Drug: Amosartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipin besylate 7.841mg+Losartan K 100mg
Study: NCT03596905
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally daily for 4 weeks
Study: NCT01935674
Drug: Continue Ritonavir-boosted PI+Rosuvastatin
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
Study: NCT00869258
Drug: Gemcitabine, docetaxel, and capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1-14: Capecitabine 1500 mg/m2/day (+/- 2days) Day 4 and 11: Gemcitabine 750 mg/m2/day (+/- 2days) Day 4 and 11: Docetaxel 30 mg/m2/day (+/- 2 days) Two week treatment regimen is followed by one week off, repeated for a total of 3 cycles
Study: NCT00636207
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dry powder inhaler
Study: NCT00190619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01551485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacebo tablet, blinded given on the first night after surgery
Study: NCT00952588
Drug: AZD1152
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg, iv, 7 day infusion
Study: NCT00413257
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: bolus NaCl during 10 min at the end of surgery and during postoperative H48
Study: NCT04496362
Drug: subcutaneous heparin anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The primary objective of this study is to evaluate the safety and efficacy of subcutaneous heparin anticoagulation compared to the standard of care systemic intravenous anticoagulation during veno-venous extracorporeal membrane oxygenation for respiratory failure. Subjects will be prospectively randomized in 1:1 ratio to subcutaneous heparin anticoagulation or systemic intravenous anticoagulation and followed until 1 week after discontinuation from ECMO support.
Study: NCT03842488
Drug: Experimental: RAL QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of 2x RAL 600mg (1200MG) once daily
Study: NCT03842488
Drug: Active comparator: DRV/cb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of DARUNAVIR/COBICISTAT 800 Mg-150 Mg once daily
Study: NCT02785185
Drug: IDP-122 Vehicle Lotion
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT02785185
Drug: IDP-122 Vehicle Cream
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT02785185
Drug: IDP-122 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion
Study: NCT02139280
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.
Study: NCT02737371
Drug: Placebo dose level A oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo adverse events days 1-10
Study: NCT02737371
Drug: F901318 Dose level B oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: F901318 adverse events days 1-10
Study: NCT02737371
Drug: Placebo dose level B oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo adverse events days 1-10
Study: NCT02737371
Drug: F901318 Dose level C oral
Normalized name: C-Time Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: F901318 adverse events days 1-10
Study: NCT02737371
Drug: Placebo Dose level C oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo adverse events days 1-10
Study: NCT01393665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03052634
Drug: RC48-ADC 1.5 mg/kg (HER2 Positive)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 1.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
Study: NCT03052634
Drug: RC48-ADC 2.5 mg/kg (HER2 Positive)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
Study: NCT03052634
Drug: RC48-ADC 2.0 mg/kg (HER2 Low Expression)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
Study: NCT01119924
Drug: Smilon®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
Study: NCT01119924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
Study: NCT01599117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
Study: NCT00833040
Drug: Sublingual sufentanil NanoTabs™ and placebo NanoTabs™
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the Titration Phase, patients titrated to the dose of sufentanil that provided adequate pain relief without intolerable side effects. Dosages were 20, 30, 40, 60 and 80 mcg. During the Double Blind Phase, patients were randomized to one of six sequences and took 7 doses of sufentanil (dosage determined in the titration phase, and 3 doses of placebo.
Study: NCT03544736
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT04488601
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT01047241
Drug: Intranasal sufentanil/ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray sufentanil+ketamine, 0,5 microg/kg sufentanil+0,5 mg/kg ketamine, single dose
Study: NCT02087241
Drug: AZD1775
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
Study: NCT01088659
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally daily, 96 weeks
Study: NCT02897011
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01161186
Drug: nab-paclitaxel, gemcitabine, capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: {nab-paclitaxel: Intravenous, 100 to 150 mg/m2 over 30 minutes once per cycle.} {gemcitabine: Intravenous, 750 to 1000 mg/m2 at 10mg/m2/minute once per cycle.} {capecitabine: oral, 500 to 1000 mg/m2 b.i.d. 7 days per cycle}
Study: NCT01487694
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo without active ingredient 1 tab daily for 12 weeks
Study: NCT02779634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill three times daily
Study: NCT00182169
Drug: Human recombinant growth hormone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00788034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT02012569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01102231
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)
Study: NCT02197975
Drug: PT010 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
Study: NCT02197975
Drug: PT010 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
Study: NCT02197975
Drug: Placebo MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo MDI. Administered as 2 inhalations
Study: NCT02483715
Drug: High-dose dual therapy (rabeprazole, amoxicillin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
Study: NCT01563406
Drug: 3.15% chlorhexidine/70% isopropyl alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.15% chlorhexidine gluconate in 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters during half of the study period.
Study: NCT00648492
Drug: Glucophage® XR 500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg, single dose fed
Study: NCT00454714
Drug: Single dose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of a single dose placebo
Study: NCT00285896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous subcutaneous placebo infusion at a dose of 4.8 pmol/kg/min for 51 hours
Study: NCT00888693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm Description for details.
Study: NCT02034773
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered once daily for up to 28 days
Study: NCT00572663
Drug: ACC (N-acetylcysteine) 1200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (ACC) 1200 mg In the 8-weeks run-in period angiotensin converting enzyme inhibitors and/or angiotensin II subtype 1 receptor antagonists were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 1200 mg N-acetylcysteine in two active treatment periods lasting 8 weeks each
Study: NCT01095939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets; oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
Study: NCT01466608
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration of rosuvastatin 20 mg once daily for 21 days.
Study: NCT01012037
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient to receive placebo tablet(s) matching linagliptin
Study: NCT02760615
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine tablets
Study: NCT00669890
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conditioning Regimen
Study: NCT00669890
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GVHD Prophylaxis
Study: NCT02587741
Drug: Novomix30
Approvals — FDA: no, EMA: no, PMDA: no
Description: started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs
Study: NCT00830544
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy
Study: NCT02388581
Drug: Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-H. pylori Therapy
Study: NCT02960217
Drug: UX007
Normalized name: UX007
Approvals — FDA: no, EMA: no, PMDA: no
Description: liquid for oral (PO) administration
Study: NCT02960217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: liquid safflower oil for PO administration
Study: NCT02650544
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in placebo arm will be orally administered placebo; along with palliative chemotherapy.
Study: NCT01501604
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 MG PO QD in cycles of 28 days
Study: NCT01356160
Drug: GS-9451 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match GS-9451 QD
Study: NCT00549692
Drug: Omega-3 fatty acid ethylester90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form :1g soft capsule Dosage : two capsules, twice a day.
Study: NCT03576508
Drug: CNTX-4975-05
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg (2mL) IA injection
Study: NCT00701285
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pravastatin 10mg once daily
Study: NCT01188369
Drug: placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion, colour identical to levosimendan
Study: NCT04611932
Drug: CKD-330 Tab. and D090 Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1T
Study: NCT03473236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo
Study: NCT04611932
Drug: CKD-333 Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1T
Study: NCT00626444
Drug: Intravenous vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks.